Low-dose adefovir dipivoxil may induce Fanconi syndrome: clinical characteristics and long-term follow-up for Chinese patients. 2015

Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

BACKGROUND Adefovir dipivoxil (ADV) nephrotoxicity is well known at a dose of 60 mg day(-1) or 120 mg day(-1). However, renal toxicity at a low-dose of 10 mg ADV for HBV-infected patients is not fully described. Our objective was to analyse the clinical features and outcomes of ADV-related Fanconi's syndrome in the Chinese population. METHODS This was a retrospective study. A total of 35 patients with ADV-related Fanconi's syndrome were studied. Clinical manifestations and biochemical parameters were analysed. 19 patients were from Peking Union Medical College Hospital (PUMCH) included from August 2010 to December 2012. A total of 16 patients were eligible from case reports in the Chinese population retrieved in PUBMED, WANFANG and CNKI database. Bone mineral density and biochemical parameters including serum phosphate, calcium, creatinine, alkaline phosphatase (ALP) were measured before and after ADV cessation and during the follow-up. RESULTS All recruited patients had hypophosphataemia, increased urinary phosphate excretion and elevated alkaline phosphatase. Serum phosphate levels rapidly increased especially within the 4 weeks after ADV cessation. Serum creatinine remained high or at the upper limit of normal range even after ADV cessation for 1 year. ALP increased in the first three months of ADV cessation and decreased at the 24th week. Bone mineral density was significantly improved after 6 months cessation of ADV. CONCLUSIONS ADV can be nephrotoxic at prolonged low doses of 10 mg. For those who take ADV long term, regular monitoring of serum phosphate, creatinine levels and urine routine tests are required.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005198 Fanconi Syndrome A hereditary or acquired form of generalized dysfunction of the PROXIMAL KIDNEY TUBULE without primary involvement of the KIDNEY GLOMERULUS. It is usually characterized by the tubular wasting of nutrients and salts (GLUCOSE; AMINO ACIDS; PHOSPHATES; and BICARBONATES) resulting in HYPOKALEMIA; ACIDOSIS; HYPERCALCIURIA; and PROTEINURIA. De Toni-Debre-Fanconi Syndrome,Lignac-Fanconi Syndrome,Proximal Renal Tubular Dysfunction,Renal Fanconi Syndrome,Adult Fanconi Syndrome,Fanconi Bickel Syndrome,Fanconi Renotubular Syndrome,Fanconi Syndrome with Intestinal Malabsorption and Galactose Intolerance,Fanconi Syndrome without Cystinosis,Fanconi-Bickel Syndrome,Glycogen Storage Disease XI,Glycogenosis, Fanconi Type,Hepatic Glycogenosis with Amino Aciduria and Glucosuria,Hepatic Glycogenosis with Fanconi Nephropathy,Hepatorenal Glycogenosis with Renal Fanconi Syndrome,Idiopathic De Toni-Debre-Fanconi Syndrome,Luder-Sheldon Syndrome,Neonatal De Toni-Debre-Fanconi Syndrome,Primary Toni-Debre-Fanconi Syndrome,Pseudo-Phlorizin Diabetes,Toni-Debre-Fanconi Syndrome,Bickel Syndrome, Fanconi,Diabete, Pseudo-Phlorizin,Diabetes, Pseudo-Phlorizin,Fanconi Syndrome, Adult,Fanconi Syndrome, Renal,Fanconi Type Glycogenosis,Fanconi-Bickel Syndromes,Lignac Fanconi Syndrome,Luder Sheldon Syndrome,Pseudo Phlorizin Diabetes,Pseudo-Phlorizin Diabete,Renotubular Syndrome, Fanconi,Syndrome, Adult Fanconi,Syndrome, Fanconi,Syndrome, Fanconi Bickel,Syndrome, Fanconi Renotubular,Syndrome, Fanconi-Bickel,Syndrome, Lignac-Fanconi,Syndrome, Luder-Sheldon,Syndrome, Renal Fanconi,Syndromes, Fanconi-Bickel
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
March 2014, Saudi medical journal,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
December 2016, Bone,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
June 2015, Journal of clinical pharmacy and therapeutics,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
June 2020, BMC pharmacology & toxicology,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
July 2017, Experimental and therapeutic medicine,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
January 2018, Drug design, development and therapy,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
April 2015, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
January 2021, Frontiers in pharmacology,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
February 2013, Clinical and experimental nephrology,
Li-Jun Xu, and Yan Jiang, and Ruo-Xi Liao, and Hua-Bing Zhang, and Jiang-Feng Mao, and Yue Chi, and Mei Li, and Ou Wang, and Xiao-Qing Liu, and Zheng-Yin Liu, and Xiao-Ping Xing, and Wei Yu, and Wei-Bo Xia
October 2020, The Journal of international medical research,
Copied contents to your clipboard!